,
,
, Ebola : retour aux origines du virus-Sciencesetavenir.fr
, Maladie à virus Ebola-Ebola-Ministère des Affaires sociales et de la Santé
,
, à la découverte du virus Ebola, 1976.
, Ebola Virus Disease Distribution Map | Ebola Hemorrhagic Fever | CDC, 2016.
, Kapstadt entdecken!
, Filoviridae-Figures-Negative Sense RNA Viruses-Negative Sense RNA Viruses, 2011.
,
The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold. Rey FA, éditeur, PLoS Pathog. 23 févr, vol.8, issue.2, p.1002550, 2012. ,
University of Texas Medical Branch at Galveston, Baron S, éditeur. Medical Microbiology, 1996. ,
, Communication Resources | Ebola Hemorrhagic Fever | CDC
,
, Gouvernement du Canada Agence de la santé publique du Canada. Virus Ebola-Fiches techniques santé-sécurité: agents pathogènes, 2001.
,
Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda. Basler CF, éditeur. PLoS Pathog, vol.4, p.1000212, 2008. ,
, Virology Images and Resources | IHII | UTMB
Les fièvres hémorragiques à virus Ebola et Marburg: l'actualité des filovirus, Médecine Trop, vol.71, issue.2, pp.111-132, 2011. ,
Great' Ebola Outbreak: A Pictorial, 2014. ,
, , 2014.
,
Ebolavirus comparative genomics. Greber U, éditeur, FEMS Microbiol Rev. sept, vol.39, issue.5, pp.764-78, 2015. ,
Analyse phylogénétique des souches du virus de la fièvre hémorragique Ebola et mise en évidence de souches atypiques ,
, Sciences & Techniques Biologiques, vol.273, 2007.
Ebola Virus Proteins. RCSB Protein Data Bank, 2014. ,
,
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor, Nature. juillet, vol.454, issue.7201, pp.177-82, 2008. ,
, Structure of the Ebola Virus Glycoprotein Bound to an Antibody from a Human Survivor
,
The Ebola Virus Matrix Protein VP40 Selectively Induces Vesiculation from Phosphatidylserine-enriched Membranes, J Biol Chem, vol.28, issue.48, pp.33590-33597, 2014. ,
Structural Rearrangement of Ebola Virus VP40 Begets Multiple Functions in the Virus Life Cycle, Cell. août, vol.154, issue.4, pp.763-74, 2013. ,
Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP, J Virol. 15 mai, vol.76, issue.10, pp.4855-65, 2002. ,
Ebola Virus VP40-Induced Particle Formation and Association with the Lipid Bilayer, J Virol. 1 juin, vol.75, issue.11, pp.5205-5219, 2001. ,
A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: Implications for filovirus budding, Proc Natl Acad Sci. 5 déc, vol.97, issue.25, pp.13871-13877, 2000. ,
A Loop Region in the NTerminal Domain of Ebola Virus VP40 Is Important in Viral Assembly, Budding, and Egress. Viruses, vol.6, pp.3837-54, 2014. ,
The Assembly of Ebola Virus Nucleocapsid Requires Virion-Associated Proteins 35 and 24 and Posttranslational Modification of Nucleoprotein, Mol Cell. août, vol.10, issue.2, pp.307-323, 2002. ,
Comparison of the Transcription and Replication Strategies of Marburg Virus and Ebola Virus by Using Artificial Replication Systems, J Virol. mars, vol.73, issue.3, pp.2333-2375, 1999. ,
Infection of Naïve Target Cells with Virus-Like Particles: Implications for the Function of Ebola Virus VP24, J Virol. juill, vol.80, issue.14, pp.7260-7264, 2006. ,
Ebola Virus VP24 Binds Karyopherin ?1 and Blocks STAT1 Nuclear Accumulation, J Virol. juin, vol.80, issue.11, pp.5156-67, 2006. ,
How a Virus Blocks a Cellular Emergency Access Lane to the Nucleus, STAT! Cell Host Microbe. 13 août, vol.16, issue.2, pp.150-152, 2014. ,
Oligomerization of Ebola Virus VP30 Is Essential for Viral Transcription and Can Be Inhibited by a Synthetic Peptide, J Biol Chem, vol.278, issue.43, pp.41830-41836, 2003. ,
Ebola Virus VP35 Protein Binds Double-Stranded RNA and Inhibits Alpha/Beta Interferon Production Induced by RIG-I Signaling, J Virol. 1 juin, vol.80, issue.11, pp.5168-78, 2006. ,
La stratégie à double tranchant du virus Ébola ,
,
,
, ViralZone: Ebolavirus cycle
,
,
, Institut Pasteur
FHV) à virus Ebola / Maladies infectieuses / Dossiers thématiques / Accueil ,
, Survivants d'Ebola : questions-réponses | Fièvre hémorragique à virus Ebola | CDC
,
, OMS | Organisation mondiale de la Santé
, WHO, p.12, 2016.
Cathepsin B & L Are Not Required for Ebola Virus Replication, PLoS Negl Trop Dis, vol.6, issue.12 ,
,
, , 2015.
,
Maladie à virus Ebola-Cours de médecine tropicale ,
,
Ebola en 7 questions ,
,
,
,
, Institut Pasteur, 2015.
, Guide opérationnel sur la lutte contre Ebola
,
, Conduite à tenir autour des cas suspects de fièvre hémorragique à virus Ebola, HCSP, 2014.
, Lignes directrices pour la collecte, le transport et la soumission d'échantillons destinés au test du virus Ebola | Fièvre hémorragique à virus Ebola | CDC
,
, , 2016.
,
Ebola : le test eZYSCREEN® fait ses preuves sur le terrain ,
eZyscreen test a strisce per diagnosticare ebola in 15 minuti ,
, , 2014.
,
, , 2016.
,
, A la Une du Républicain Lorrain : toute l'actualité de la Moselle
Ébola progresse en Afrique de l'Ouest ,
,
Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak, Science. 12 sept, vol.345, issue.6202, pp.1369-72, 2014. ,
Ebola : quels sont les pays concernés par l'épidémie ? ,
, , 2014.
,
Ebola Virus Disease in the Democratic Republic of Congo, N Engl J Med, vol.371, issue.22, pp.2083-91, 2014. ,
, Ebola et autres fièvres hémorragiques-Activités | Médecins Sans Frontières, p.12, 2016.
, maladie à virus Ebola
équipement de protection individuelle dans le cadre de la riposte à la flambée d'infections à filovirus ,
Caisse des Français de l'Etranger, 2016. ,
,
, Mission des Nations Unies pour l'action d'urgence contre l'Ebola (MINUAUCE) [Internet]. Action mondiale de lutte contre l'Ebola, 2015.
,
, Ebola-Maladies infectieuses-Ministère des Affaires sociales et de la Santé
,
,
, Ministère des Affaires étrangères et du Développement international, 2016.
, Ebola : le nouveau centre de traitement MSF au Liberia déjà débordé par le nombre de patients-Articles | Médecins Sans Frontières
,
, , 2016.
,
, Ebola : « Le chlore est notre meilleur allié
, , 2017.
, Le centre de traitement Ebola de Macenta accueille ses premiers patients
, , 2016.
, Urgence Ebola-Dossiers | Médecins Sans Frontières, 2016.
,
Visite d'un centre de traitement d'Ebola-Sciencesetavenir.fr ,
, Témoignage d'un patient guéri d'Ebola : « Ebola, ce n'est pas forcément la mort
,
Advancements in the Therapy of Ebola Virus Disease. Pediatr Infect Dis Open Access, 2016. ,
,
Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease, N Engl J Med. 7 janv, vol.374, issue.1, pp.23-32, 2016. ,
, , 2016.
, OMS | Traitements et vaccins potentiels contre le virus Ebola, 2016.
,
Trois traitements expérimentaux contre Ebola autorisés en France. Le Monde.fr [Internet]. 19 sept, 2014. ,
,
Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics. mBio, 27 févr, vol.6, issue.1, pp.2227-2241, 2015. ,
, Le virus Ebola s'est adapté à mieux infecter l'homme lors de l'épidémie de, pp.2013-2016
, Institut Pasteur
,
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea, N Engl J Med. 7 janv, vol.374, issue.1, pp.33-42, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01252702
Preparation and Use of Hyperimmune Serum for Prophylaxis and Therapy of Ebola Virus Infections, J Infect Dis. févr, vol.179, issue.s1, pp.218-241, 1999. ,
, Memoire Online-Utilisation des produits biologiques d'origine équine en thérapeutique humaine-Geraud Chancelin HELLOW TEJIOZEM
, , p.21
Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection, Sci Rep. 12 avr, vol.6, p.24179, 2016. ,
, Antibody Fragmentation | Innova Biosciences
,
, , 2016.
,
,
Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. Sundquist WI, éditeur, J Virol. 1 sept, vol.90, issue.17, pp.7618-7645, 2016. ,
, OGM contre Ebola-Afis-Association française pour l'information scientifique, 2016.
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp, Nature, vol.29, issue.2014 ,
,
A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection, N Engl J Med, vol.375, issue.15, pp.1448-56, 2016. ,
, WHO | Table of drug clinical trials, 2016.
,
, Bavituximab Oncology
, Peregrine Pharmaceuticals PPHM Board [Internet]. Investors Hub
,
Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions, J Immunol Res, vol.2015, pp.1-9, 2015. ,
, BioCryst Pharmaceuticals Inc, p.4430
,
BCX4430-A broadspectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease, J Infect Public Health. mai, vol.9, issue.3, pp.220-226, 2016. ,
BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model ,
, Positive-Study-Results-for-BCX4430-Delayed-Treatment-of-Ebola-Virus-Infection-in-aNon-Human-Primate-Model.html, 2016.
, A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430Full Text View-ClinicalTrials.gov [Internet
, , 2016.
,
, The New Drug Application Approval of "AVIGAN? Tablet 200mg" in Japan for the anti-influenza virus drug
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res. mai, vol.105, pp.17-21, 2014. ,
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. Lipsitch M, éditeur, PLOS Med. 1 mars, vol.13, issue.3, p.1001967, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01327168
, Résultats préliminaires de l'essai clinique JIKI visant à tester l'efficacité du favipiravir pour réduire la mortalité chez les personnes infectées par le virus Ebola en Guinée
, Résultats définitifs de l'essai JIKI
Treatment of Ebola virus infection with brincidofovir, 2016. ,
,
, Chimerix's Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa by International Consortium (NASDAQ:CMRX)
InterferonTherapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever, J Infect Dis. 15 juill, vol.208, issue.2, pp.310-318, 2013. ,
Interferon-? Inhibits Ebola Virus Infection. Schnell MJ, éditeur, PLOS Pathog, vol.11, issue.11, p.1005263, 2015. ,
Special report: Ebola's thin harvest, vol.31 ,
,
, TDR | New trial of TKM-Ebola treatment to start in Sierra Leone, 2016.
, Tekmira Provides Update on TKM-Ebola-Guinea, 2016.
, Ebola Virus Infection: a review on the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials-document
Knocking down barriers: advances in siRNA delivery, Nat Rev Drug Discov. févr, vol.8, issue.2, pp.129-167, 2009. ,
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study, The Lancet. mai, vol.375, issue.9729, pp.1896-905, 2010. ,
, Experimental Ebola drug shelved; study explores virus clearance
, CIDRAP, 2016.
,
Ebola Drug by Tekmira May Be Used on Infected Patients, vol.8 ,
,
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates, Nature. 22 avr, vol.521, issue.7552, pp.362-367, 2015. ,
Progression of Ebola Therapeutics During the 20142015 Outbreak, Trends Mol Med. 1 févr, vol.22, issue.2, pp.164-73, 2016. ,
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. von Seidlein L, éditeur, PLOS Med. 19 avr, vol.13, issue.4, p.1001997, 2016. ,
, AVI-7537) Drug Therapy (Sarepta Therapeutics) for Treating Ebola Virus Disease, ECRI Institute, vol.6002
Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses, vol.4, pp.2806-2836, 2012. ,
A Single Phosphorodiamidate Morpholino Oligomer Targeting VP24 Protects Rhesus Monkeys against Lethal Ebola Virus Infection. mBio, 27 févr, vol.6, issue.1, pp.2344-2358, 2015. ,
Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies ,
, Antimicrob Agents Chemother, vol.58, issue.11, pp.6639-6686, 2014.
, ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola | Business Wire, p.15, 2014.
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys, The Lancet. déc, vol.362, issue.9400, pp.1953-1961, 2003. ,
, Ebola news n°10, mars 2016 | Société Française de Médecine de Catastrophe, 2016.
Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication, Viruses. 1 déc, vol.7, issue.12, pp.6233-6273, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01911432
, OMS | Innocuité de 2 vaccins candidats contre le virus Ebola
,
, OMS sur l'accès aux vaccins contre la maladie à virus Ebola et le financement de ces vaccins
, , 2016.
Clinical development of Ebola vaccines, Ther Adv Vaccines. sept, vol.3, p.125, 2015. ,
Chimpanzee Adenovirus Vector Ebola Vaccine-Preliminary Report, N Engl J Med, p.150126054808000, 2014. ,
, OMS | Innocuité de 2 vaccins candidats contre le virus Ebola
, Deux vaccins contre Ebola passent en phase 3
, , 2016.
, Initial results of Ebola vaccine trials in Kenya show it is safe-News [Internet]. [cité 30 mai, 2017.
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses, Nat Med. juill, vol.11, issue.7, pp.786-90, 2005. ,
Un vaccin contre les virus Ebola et Marburg : des résultats prometteurs. Virologie. 30 sept, vol.9, pp.413-417, 2005. ,
VSVEBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain, Science. 14 août, vol.349, issue.6249, pp.739-781, 2015. ,
Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona, J Infect Dis, vol.214, issue.3, pp.360-366, 2016. ,
, OMS | Innocuité de 2 vaccins candidats contre le virus Ebola
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial, The Lancet. août, vol.386, issue.9996, pp.857-66, 2015. ,
Trial to Introduce a Vaccine against Ebola (STRIVE) Q&A | Ebola Hemorrhagic Fever | CDC ,
, , 2016.
,
, Profectus Ebola Vaccine Ph1 Initiation, 2016.
,
Safety and Immunogenicity of Novel Adenovirus Type 26-and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial, JAMA. 19 avr, vol.315, issue.15, p.1610, 2016. ,
Lancement d'une étude sur le virus Ebola, 2016. ,
, Inserm recrute environ 300 volontaires pour un essai vaccinal contre le virus Ebola, 2015.
, Interruption d'un essai clinique pour un vaccin contre Ebola, 2016.
, A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults-Full Text View-ClinicalTrials
, A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants-Full Text View-ClinicalTrials
,
, Inovio Ebola Vaccine Generates Robust Immune Responses in Humans, 2016.
, Inovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen, 2016.
, Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers-Full Text View-ClinicalTrials
,
, Présidente internationale de MSF, devant les Nations Unies-Publications | Médecins Sans Frontières
,
, OMS | Rapport du Groupe d'experts chargé de l'évaluation intérimaire de la riposte à Ebola
, , 2016.
,
, OMS | Règlement sanitaire international, 2005.
,